Built for this moment — a founding team with deep expertise in antibody engineering, cardiovascular therapeutics, and biotech company building, supported by strategic advisors from top pharma and life science organizations.
Tatiana Blanchard, PhD
Co-founder & CEO, Laurel Biotherapeutics
University of Pennsylvania. Former RA Capital. Deep expertise in antibody drug development and cardiovascular therapeutics.
Matt Therkelsen, PhD
Co-founder & Executive Chairman, Laurel Biotherapeutics
Principal of Taurus Bioventures. Former elevatebio, RA Capital, Purdue University. Operational and scientific domain expertise in life science software, drug discovery services, and biotech financing.
Michael DiBiasio-White, PhD
Co-founder & Head of R&D, Laurel Biotherapeutics
Former affinia Therapeutics, MedImmune, Purdue University. Expertise in antibody discovery, VHH engineering, and preclinical development.
Mathieu Ghadanfar, MD
Clinical Development
Novartis, Pfizer
David Gordon, PhD
Cardiovascular Drug Discovery
Bristol Myers Squibb
Jochen Reiser, MD, PhD
Renal Drug Discovery
UTMB, Walden Biosciences
Stephanie Oestreich, PhD
Strategic & Business Development
MIT, Novartis, RA Capital
Sam Hoare, PhD
Catherine Hutchings, PhD
Janine Schuurman, PhD
Toon Laeremans, PhD
This is not a blind pool. Matthew Therkelsen is both co-founder of Laurel and the principal of Taurus Bioventures — SPV investors access a deal sourced from the inside, at seed terms, alongside Mission BioCapital.